NEW YORK, Aug. 2 – Compugen has licensed its LEADS computational biology platform to Novartis, the company announced on Thursday.
The deal, which will run for one year with the option to extend to two, also includes a proprietary DNA chip design to represent Novartis’ transcriptome database. While Compugen would not disclose financial details of the arrangement, a company spokesperson revealed that it was in the “multi-million dollar per year” range.
“Compugen will analyze both EST and genomic databases to create for Novartis a reliable representation of transcriptomes of various organisms,” Mor Amitai, CEO of Compugen, said in a statement.
The LEADS bioinformatics platform incorporates genomics and proteomics tools and public and proprietary databases.